Pemetrexed

• CAT Number: I001434
• CAS Number: 137281-23-3
• Molecular Formula: C₂₀H₂₁N₅O₆
• Molecular Weight: 427.41
• Purity: ≥95%
• Target: Autophagy
• Solubility: DMSO 1mg/mL Water 94 mg/mL Ethanol <1 mg/mL
• Storage: 2-8°C(protect from light)
• IC50: 1.3nM(Ki for TS); 7.2nM(DHFR); 65nM(GARFT)
• IUPAC Name: (2S)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
• InChI: InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1
• InChIKey: WBXPDJSOTKVWSJ-ZDUSSCGKSA-N
• SMILES: C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O

Pemetrexed（Cat No.:I001434）is a multi-targeted antifolate chemotherapeutic agent used primarily in the treatment of malignant pleural mesothelioma and non-small cell lung cancer (NSCLC). It works by inhibiting several key enzymes involved in folate-dependent processes, including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This inhibition disrupts DNA synthesis and cell division, particularly in rapidly dividing cancer cells. Pemetrexed is a cornerstone in oncology research for exploring novel cancer treatments and combination therapies, making it a vital component in clinical and pharmaceutical studies aimed at improving patient outcomes.

Reference

[1]. Shih C, Chen VJ, Gossett LS, LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997 Mar 15;57(6):1116-23.

[2]. Müller C, Reddy JA, Leamon CP, Effects of the antifolates pemetrexed and CB3717 on the tissue distribution of (99m)Tc-EC20 in xenografted and syngeneic tumor-bearing mice. Mol Pharm. 2010 Apr 5;7(2):597-604.

[3]. Rudin CM, Brahmer JR, Juergens RA, Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer.J Thorac Oncol. 2013 May;8(5):619-23.